Effects of atorvastatin on renal angiotensin-converting enzyme 2 expression in hypertensive rats

Abstract

Abstract: AIM: To observe the effects of atorvastatin on the expressions of renal angiotensin-converting enzyme 2 (ACE2) in two kidney and one-clip (2K1C) hypertensive rats and to explore new possible mechanism of atorvastatin in decreasing systolic blood pressure(SBP). METHODS: 40 male Wistar rats were randomly divided into five groups (8 in each group): sham operation group, 2K1C hypertension group, 2K1C +valsartan group(20 mg·kg^-1·d^-1), low dose atorvastatin group (10 mg·kg^-1 ·d^-1) and high dose atorvastatin group(30 mg·kg^-1 ·d^-1). SBP was measured by tail-cuff method before and one week after operation as well as 4 weeks and 8 weeks after drug intervention. After 8 weeks the renal ACE2 protein expression, myocardial Ang Ⅱ level and kidney ACE2 mRNA expression were determined by immunohistochemistry, radioimmunoassay and RT-PCR, respectively. RESULTS: The SBP and angiotensin Ⅱ concentration of rat myocardial tissue in high dose atorvastatin group were significantly decreased compared with those of the hypertension group (P<0.01). RT-PCR results showed that the levels of renal ACE2 mRNA expression in hypertension group was decreased to a certain extent compared with those of the Valsartan group, low and high doses of atorvastatin groups (P<0.05). CONCLUSION: Kidney ACE2 protein and ACE2 mRNA expression are deceased in 2K1C hypertensive rats. The SBP and the concentration of angiotensin Ⅱin rat cardiac tissue are decreased and the expressions of ACE2 and ACE2mRNA in renal tissue are increased in atorvastatin groups.

Key words: hypertension, angiotensin-converting enzyme 2, angiotensin Ⅱ, atorvastatin

CLC Number:

R965.2

ZHANG Lin-ye, XING Wen, WANG An-cai. Effects of atorvastatin on renal angiotensin-converting enzyme 2 expression in hypertensive rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(11): 1243-1248.

References

[1] Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin- convertingenzym-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9[J]. Circ Res, 2000, 87(5): E1-E9.
[2] Hamming I, Timens W, BulthuisML, et al. Tisstle dlstribution of ACE2 protein, the functional receptor for SARS coronavirus.A first step in understanding SARS pathogenesis[J]. J Pathol, 2004, 203(2): 631-637.
[3] Wei CC, Meng QC, Palmer R, et al. Evidence for angiotensin- converting enzyme and chymase mediated angiotensin Ⅱ formation in the intersitial fluid space of the dog heart in vivo[J]. Circulation, 1999, 99(19): 2583-2589.
[4] Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzymerelated carboxypeptidase[J]. J Biol Chem, 2002, 277(17): 14838-14843.
[5] Iwata M, Cowling RT, Gurantz D, et al. Angiotensin (1 -7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects[J]. Am J Physiol Heart Circ Physiol, 2005, 289(6): H2356-2363.
[6] Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin (1 -7)[J]. Am J Physiol Heart Circ Physiol, 2007, 292(2): H736-742.
[7] Fan X, Wang Y, Sun K, et al. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women[J]. Clin Pharmacol Ther, 2007, 82(2): 187-196.
[8] Crackower MA, Sarao R, Oudit GY, Angiotensin-converting enzyme 2 is an essential regulator of heart function[J]. Nature, 2002, 417(6891): 822-828.
[9] Laufs U, La Fata V, Plutzky J, et al. Upregulatlon of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors[J]. Circulation, 1998, 97(12): l129-1135.
[10] Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis innormocholesterolemic animals[J]. NatMed, 2000, 6(9): 1004-1010.
[11] Rikitake Y, Kawashima S, Takeshita S, et al. Antioxidative properties of fluvastatin an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits[J]. Atherosclerosis, 2001, 154(1): 87-96.
[12] Hemandez-Perem O, Perez-Sala D, Navam-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatinand simvastatln, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothehal cells[J]. J Clin Invest, 1998, 101(12): 2711-2719.
[13] Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species[J]. Hypertension, 2001, 137(6): 1450-1457.
[14] Ichi T, Takeda K, Tokunou T, et al. Downregulation of angloteusin II type l receptorby hydrophobic 3-hydroxy-3- methy lghtaryl coenzyme A reductase inhibitors in vascular smooth muscle cells[J]. Arteriosder Thromb Vase Bil, 200l, 21(12): 1895-1901.
[15] Delbosc S, Cristol JP, Descomps B, et al. Simvastatin attemaltea cardiovaseularefects and oxidative stress inducde by angiotensin Ⅱ[J]. Arch Mal Coeur Vaiss, 2001, 94(11): 1199-1202.
[16] 吴逸南, 葛志明, 姜虹, 等. 血管紧张素转换酶2在自发性高血压大鼠肾脏表达与血压的关系研究[J]. 中国病理生理杂志, 2006, 22(4): 818-820.
[17] 王安才, 曹蘅, 汪俊元, 等. 阿托伐他汀对自发性高血压大鼠去外膜颈动脉内膜增生的影响[J]. 中国动脉硬化杂志, 2006, 14(10): 862-866.